Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed?
Bicara Therapeutics (BCAX) has seen a 13.5% stock increase following its lead candidate, ficerafusp alfa, receiving FDA Breakthrough Therapy Designation and entering a pivotal Phase III trial. Despite a higher net loss of US$137.95 million in 2025, an oversubscribed public offering and shelf registration for stock have extended its cash runway into the first half of 2029. This stronger financial position and clinical advancement support the company's investment narrative, although future expansion may still require additional capital.
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed?
Bicara Therapeutics (BCAX) saw a 13.5% increase in stock price after its lead candidate, ficerafusp alfa, received FDA Breakthrough Therapy Designation and entered a pivotal Phase III trial. Despite a higher net loss of US$137.95 million in 2025, the company strengthened its balance sheet with an oversubscribed public offering, extending its cash runway into the first half of 2029. This development raises questions about its investment narrative and ability to manage rising losses against expanding clinical ambitions.
Bicara Therapeutics Announces Inducement Grant
Bicara Therapeutics, a clinical-stage biopharmaceutical company, has announced an inducement grant of stock options to new employees under Nasdaq Listing Rule 5635(c)(4). This move aims to attract and retain top talent as the company advances its clinical pipeline. The grant includes options to purchase 75,000 shares of common stock at an exercise price of $25.50 per share, vesting over four years.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to a new employee under its 2026 Inducement Plan, as a material incentive for employment. The grant consists of a non-qualified stock option to purchase 44,175 shares of common stock at an exercise price of $20.50 per share. This award, approved by the compensation committee, was made in accordance with Nasdaq Listing Rule 5635(c)(4).
New Bicara hire gets stock option for 44,175 shares at $20.50
Bicara Therapeutics granted a new employee a non-qualified stock option for 44,175 shares at an exercise price of $20.50, matching the Nasdaq closing price on April 1, 2026. This inducement grant, made under Bicara's 2026 Inducement Plan and approved by an independent compensation committee, vests 25% after one year, with the remainder vesting in 12 equal quarterly installments. The award aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's routine equity-related and HR-focused disclosures.
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings
HC Wainwright analysts have increased their Q1 2026 EPS estimate for Bicara Therapeutics (NASDAQ: BCAX) to ($0.64) from ($0.72) while maintaining a "Buy" rating and a $42 price target. This adjustment follows Bicara beating Q4 expectations with ($0.68) EPS against a ($0.72) consensus and management's report of a stronger cash position. Despite significant insider selling, major institutional investors like T. Rowe Price and Janus Henderson increased their stakes, contributing to a "Moderate Buy" consensus rating among analysts, with an average target price of $28.00.
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
Wall Street analysts are optimistic about Bicara Therapeutics Inc. (BCAX), predicting a potential upside of 54.9% based on an average price target of $30.8. Despite inherent skepticism around price targets, the strong agreement among analysts and positive earnings estimate revisions suggest potential for stock growth. BCAX currently holds a Zacks Rank #2 (Buy), further indicating a favorable outlook for the near term.
Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for Bicara Therapeutics Inc. common stock (NASDAQ:BCAX). The full content of the transcript is expected to provide detailed financial results and commentary from the company's management.
Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading
Wall Street analysts predict Bicara Therapeutics Inc. (BCAX) could see a 54.85% surge, with an average price target of $30.80. Despite the 11% climb in the last month to $19.89, experts highlight increased earnings forecasts and a Zacks Rank #2 (Buy) as strong indicators for further upside. Investors are cautioned to approach price targets with skepticism, but the low standard deviation in analyst forecasts and positive earnings revisions suggest potential for growth.
Bicara Therapeutics (Nasdaq:BCAX) - Stock Analysis
Bicara Therapeutics Inc. (Nasdaq:BCAX) is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with a market cap of US$1.3 billion and currently trading at US$19.89. The company is considered 34.8% undervalued with an analyst consensus target of US$30.5. Key developments include advancements in its FICERA program for HPV-negative head and neck cancer and recent equity offerings.
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade
Bicara Therapeutics (NASDAQ:BCAX) reached a new 52-week high after Goldman Sachs raised its price target, amidst a "Moderate Buy" consensus rating from analysts. Despite recent insider selling, Bicara reported strong Q4 results, beating EPS estimates, and highlighted a healthy cash runway, supporting its ongoing clinical programs. The company's lead candidates, PST-001 and PST-002, target psychiatric and neurological disorders.
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX)
Three analysts have issued bullish sentiments on healthcare companies Lexeo Therapeutics, Bicara Therapeutics Inc., and Compass Therapeutics. Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Lexeo Therapeutics with a $19.00 price target, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. with a $36.00 price target, and Stephen Willey from Stifel Nicolaus maintained a Buy rating on Compass Therapeutics with a $12.00 price target. All three companies show strong buy analyst consensus and significant upside potential from current levels.
Bicara Therapeutics (Nasdaq: BCAX) outlines pivotal ficerafusp alfa cancer program
Bicara Therapeutics (BCAX) has detailed its pivotal ficerafusp alfa cancer program, focusing on a global Phase 2/3 clinical trial (FORTIFI-HN01) for first-line HPV-negative head and neck squamous cell carcinoma, with target enrollment by late 2026 and an interim analysis mid-2027. Early Phase 1/1b data for ficerafusp alfa in combination with pembrolizumab showed a 54% overall response rate and a median overall survival of 21.3 months in this patient group, leading to the selection of a 1500mg weekly dose for the pivotal trial. The company is also exploring the therapy in other squamous cell carcinomas and colorectal cancer, leveraging ficerafusp alfa's dual EGFR/TGF-β inhibition to enhance tumor penetration and immune response while maintaining a manageable safety profile.
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday
This article compiles recent analyst rating changes and price target adjustments for ten different companies. HC Wainwright & Co. increased its price target for Bicara Therapeutics Inc. (BCAX) to $42, suggesting a significant rally potential. Other companies mentioned include Abbott Laboratories (ABT), BTCS Inc. (BTCS), Phreesia, Inc. (PHR), nCino, Inc. (NCNO), Shake Shack Inc. (SHAK), Corpay, Inc. (CPAY), Viridian Therapeutics, Inc. (VRDN), and USA Rare Earth, Inc. (USAR), with analysts issuing a mix of upgrades, downgrades, and price target revisions.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics announced its financial results for Q4 and full year 2025, highlighting significant progress in its FORTIFI-HN01 pivotal trial for ficerafusp alfa in HPV-negative head and neck cancer. The company selected a 1500mg weekly optimal dose and initiated Phase 3, expecting interim analysis by mid-2027. Bicara also raised $161.8 million in a public offering, fortifying its financial position to fund operations into the first half of 2029.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress in its clinical trials, particularly for ficerafusp alfa in HPV-negative head and neck cancer. The company selected an optimal dose for ficerafusp alfa, initiated Phase 3 of the FORTIFI-HN01 trial, and secured substantial funding of $161.8 million through a public offering to support commercialization efforts and further development. Bicara anticipates continued advancements, including long-term follow-up data presentations and the achievement of critical enrollment milestones.
Bicara Therapeutics Inc. initiates Phase 3 trial with 1500 mg QW dose for FORTIFI-HN01
Bicara Therapeutics Inc. has initiated a Phase 3 clinical trial for its FORTIFI-HN01 program, using a 1500 mg once weekly (QW) dosage for patients with HPV-negative head and neck squamous cell carcinoma (HNSCC). The company is also developing a Q3W maintenance strategy and has begun a study for first-line recurrent or metastatic HPV-negative HNSCC patients. Bicara Therapeutics plans to provide further updates on these developments during a scheduled conference call.
Bicara Therapeutics 2025 Financial Update
Bicara Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $138.0 million and an EPS net loss of $(2.52) for the full year 2025, with no revenue generated. The company ended 2025 with $414.8 million in cash, cash equivalents, and marketable securities, expecting these funds to support operations into the first half of 2029. Research and development expenses for the year totaled $125.1 million.
Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data
Bicara Therapeutics (BCAX) saw its stock surge over 7.5% in premarket trading following its Q4 2025 earnings call, driven by a strong cash position strengthened by a $161.8 million public offering and promising clinical data for its lead head and neck cancer treatment, ficerafusp alfa. The company reported $414.8 million in cash, with a runway extending into the first half of 2029, supporting ongoing pivotal studies and future commercialization efforts despite increased operating expenses. Clinical results indicate that ficerafusp alfa significantly improves overall response rates and duration of response compared to standard of care, particularly in HPV-negative head and neck cancer.
Bicara Therapeutics 2025 Financial Update
Bicara Therapeutics, a clinical-stage biopharmaceutical company, reported no revenue for 2025 but posted a net loss of $138.0 million for the year, with an EPS net loss of $(2.52). The company ended 2025 with $414.8 million in cash reserves and expects this capital to fund operations into the first half of 2029, with research and development expenses totaling $125.1 million.
Cash runway to 2029 as Bicara (NASDAQ: BCAX) advances Phase 3
Bicara Therapeutics announced its financial results for the full year 2025, reporting a net loss of $137.95 million due to increased R&D and administrative expenses. The company has secured funding to extend its operational runway into the first half of 2029, with $414.8 million in cash and an additional $161.8 million from a recent offering. Bicara also provided updates on its lead oncology program, ficerafusp alfa, including the initiation of a pivotal Phase 3 trial for HPV-negative head and neck cancer, with an interim analysis expected in mid-2027.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress in its clinical trials, particularly the advancement of its FORTIFI-HN01 study for HPV-negative head and neck cancer. The company selected a 1500mg weekly dose of ficerafusp alfa as optimal and initiated Phase 3, with interim analysis expected mid-2027. Bicara also raised $161.8 million in net proceeds through a public offering to support future commercialization and development efforts, extending its cash runway into the first half of 2029.
Bicara moves head and neck cancer drug into Phase 3 after dose pick
Bicara Therapeutics announced its fourth quarter and full year 2025 financial results, alongside significant business updates. The company has moved its head and neck cancer drug, ficerafusp alfa, into Phase 3 of the FORTIFI-HN01 trial after selecting the optimal 1500mg dose and anticipates an interim analysis by mid-2027. Bicara also reported a robust cash position of $414.8 million as of December 31, 2025, further bolstered by a $161.8 million public offering in Q1 2026, extending its cash runway into the first half of 2029.
Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bicara Therapeutics Inc. (NASDAQ: BCAX) is set to release its fourth-quarter earnings on Monday, March 30, with analysts anticipating a loss of 65 cents per share. Ahead of this, several prominent analysts have revised their forecasts, with B of A Securities initiating coverage with a Buy rating and others maintaining Outperform or Buy ratings, while some hold Neutral or Equal-Weight positions. These analyst ratings range from price targets of $18 to $35.
Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bicara Therapeutics (NASDAQ: BCAX) is set to release its fourth-quarter earnings on March 30, with analysts expecting a wider loss per share of 65 cents compared to 39 cents in the prior year. Several financial analysts have recently updated their ratings and price targets for the company, including Buy ratings from B of A Securities and BTIG, an Outperform from Wedbush, a Neutral from Mizuho, and an Equal-Weight from Wells Fargo.
Bicara Therapeutics (BCAX) CMO executes 5,500-share 10b5-1 trade
Bicara Therapeutics Chief Medical Officer David Raben executed a pre-arranged 10b5-1 trading plan, involving the exercise of options for 5,500 shares at $3.7898 each and the subsequent sale of those shares at a weighted average price of $18.9508. Following these transactions, Raben directly holds 55,286 shares of the company's common stock. The transaction was filed as an SEC Form 4 and was pre-scheduled on February 12, 2025.
Bicara therapeutics chief medical officer sells $104,229 in shares
Bicara Therapeutics Chief Medical Officer, David Raben, sold 5,500 shares of common stock for over $104,000, while simultaneously exercising options to acquire 5,500 shares. These transactions occurred just before the company's earnings report, with the stock trading near its 52-week high. The company recently completed a significant stock offering and received favorable analyst coverage, though InvestingPro analysis suggests the stock might be overvalued.
B of A Securities initiates coverage of Bicara Therapeutics (BCAX) with buy recommendation
B of A Securities has initiated coverage of Bicara Therapeutics (BCAX) with a "buy" rating. This indicates a positive outlook from the financial institution regarding the company's stock performance and future prospects. Investors will likely watch Bicara Therapeutics closely following this new recommendation.
Bicara Therapeutics (BCAX) CFO exercises options and sells 9,200 shares under 10b5-1 plan
Bicara Therapeutics Inc.'s Chief Financial Officer, Hyep Ivan, exercised stock options for 9,200 shares and subsequently sold all 9,200 shares on March 23, 2026. This transaction was part of a pre-planned Rule 10b5-1 trading plan established on February 13, 2025. Following these actions, Ivan directly owns 145,355 shares of the company's common stock.
BCAX (NASDAQ: BCAX) issuer to sell 5,500 shares; insider sales disclosed
Bicara Therapeutics Inc. (NASDAQ: BCAX) has disclosed an issuer-related planned sale of 5,500 common shares on March 25, 2026, stemming from an exercise of stock options. The Form 144 filing also reveals recent insider sales by David Raben, totaling 16,500 shares across two transactions in early March 2026 for a combined value of over $300,000. These transactions are detailed in the SEC Form 144.
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a "Buy" rating and a $35 price objective, projecting its lead drug ficerafusp alfa (ficera) could become the new standard of care for first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. Early clinical data shows superior objective response rates and progression-free survival compared to current treatments. The firm estimates ficera could achieve $1 billion in risk-adjusted peak sales by 2037 and sees expansion opportunities beyond head and neck cancer.
BCAX: B of A Securities Initiates Coverage with 'Buy' Rating | B
B of A Securities has initiated coverage on Bicara Therapeutics (BCAX) with a 'Buy' rating and a price target of $35.00, indicating strong confidence. This new rating adds to a trend of favorable analyst ratings for BCAX, including recent "Outperform" and "Buy" ratings from other firms. The average analyst price target for BCAX is $29.75, implying a potential upside of 63.82% from its current price, with an overall "Outperform" consensus recommendation from brokerage firms.
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 9,200 Shares
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of the company's stock on March 23rd at an average price of $18.52, totaling $170,384. This sale reduced his ownership by 5.95%, bringing his total direct holdings to 145,355 shares. The company's stock is currently trading around $18, with a market capitalization of $994.80 million, and analysts have a "Moderate Buy" consensus rating with an average target price of $30.25.
Ivan Hyep, Bicara Therapeutics CFO, sells $170k in BCAX stock
Bicara Therapeutics CFO Ivan Hyep sold 9,200 shares of BCAX stock for $170,348 after exercising options to acquire the same number of shares. The sale was executed under a Rule 10b5-1 trading plan. Following the transactions, Hyep directly owns 145,355 shares of the company.
Bicara Therapeutics Inc. schedules March 30 Q4 and 2025 earnings call for investors
Bicara Therapeutics Inc. announced it will release its Q4 and full year 2025 financial results on Monday, March 30. The company will also host a conference call for investors and analysts at 8:30 AM ET on the same day to provide a business update and discuss its financial performance and future outlook. This announcement follows previous research by Bicara Therapeutics focusing on fibrotic, resistant HPV-negative solid tumors and efforts in patient advocacy.
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. (Nasdaq: BCAX) announced it will report its fourth quarter and full year 2025 financial results and provide business updates before market open on Monday, March 30, 2026. The company will also host a conference call at 8:30 a.m. ET on the same day to discuss the results. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, currently under development.
Bicara Therapeutics to Report Fourth Quarter and Full Year
Bicara Therapeutics Inc. announced it will report its fourth quarter and full year 2025 financial results and business updates on Monday, March 30, 2026, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these results. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with their lead program being ficerafusp alfa.
BCAX Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Bicara Therapeutics Inc (BCAX), detailing its profitability metrics, including N/A gross, operating, and net margins, and a Return on Equity (ROE) of -26.64%. It also highlights BCAX's market capitalization of $1.01B and compares its efficiency with competitors MLTX and ORIC. The revenue breakdown sections are noted as having no available data.
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus "Moderate Buy" rating from analysts, with an average one-year target price of $30.25. Despite analyst upgrades and institutional investment, company insiders including the CFO and CEO have recently sold shares. The company, focused on neurohormone-based therapies, has a market capitalization of $1.01 billion and trades within a 52-week range of $7.80-$20.25.
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 6,905 Shares
Bicara Therapeutics CEO Claire Mazumdar sold 6,905 shares of the company's stock on March 19th for $129,675.90, reducing her position by 1.99%. This is part of a series of sales in March totaling approximately 60,000 shares for $1.14 million, leaving her with 339,392 shares. Following this news, BCAX stock traded down about 2% to $18.41, though analysts maintain a "Moderate Buy" rating with an average target price of $30.25.
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $30,244.20 in Stock
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,596 shares of the company's stock for $30,244.20 on March 20, 2026, reducing her stake by 0.47%. This sale is part of several recent disposals by the CEO. Despite the insider selling, institutional investors have increased their positions in BCAX, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $30.25.
Bicara therapeutics CEO Mazumdar sells $282k in BCAX stock
Bicara Therapeutics CEO Claire Mazumdar sold 14,900 shares of BCAX stock for approximately $282,365 between March 18 and March 20, 2026. Concurrently, she exercised options to acquire the same number of shares for $56,847. This comes after a significant 80% rally in the stock over the past six months and a recent successful public offering by the company, raising $172.5 million.
Bicara Therapeutics (BCAX) CEO sells 15,000 shares after option exercise
Bicara Therapeutics (BCAX) CEO Claire Mazumdar exercised stock options for 15,000 shares and subsequently sold those shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred over three days at weighted-average prices between $18.73 and $19.26 per share. Following these transactions, Mazumdar directly holds 339,392 shares of the company's common stock.
BCAX (NASDAQ: BCAX) affiliate sells shares; planned 1,596‑share option exercise
An affiliate of Bicara Therapeutics Inc. (NASDAQ: BCAX) has filed a Form 144, disclosing a planned sale of 1,596 shares through the exercise of stock options on March 20, 2026. The filing also details multiple past dispositions in March 2026 by Claire Mazumdar, listing specific share counts and gross proceeds for each transaction. Analysts view these disclosures as routine compliance for affiliate liquidity, noting no material corporate action or market impact is quantified in this filing.
[144] Bicara Therapeutics Inc. SEC Filing
This SEC filing (Form 144) for Bicara Therapeutics Inc. (BCAX) details a proposed sale of 6,905 shares of common stock by Claire Mazumdar on March 19, 2026, following the exercise of stock options for cash. The filing also lists prior dispositions by Mazumdar in the preceding three months, amounting to 36,766 shares on March 9, 2026, and 6,499 shares on March 18, 2026, among others. This is described as a routine disclosure regarding an insider's intent to sell shares after an option exercise.
Cantor Fitzgerald L. P. Takes $1.58 Million Position in Bicara Therapeutics Inc. $BCAX
Cantor Fitzgerald L.P. recently acquired a new position of 100,000 shares in Bicara Therapeutics Inc. (NASDAQ: BCAX) valued at approximately $1.58 million. This makes them a significant stakeholder, owning 0.18% of the company. Other institutional investors have also adjusted their holdings in Bicara Therapeutics, while some insiders have sold shares.
Affiliate plans to sell 6,499 BCAX shares (NASDAQ: BCAX)
An affiliate of Bicara Therapeutics Inc. (NASDAQ: BCAX) has filed Form 144 to sell 6,499 common shares, which are to be sold on March 18, 2026, following the exercise of stock options. The filing also details prior dispositions by Claire Mazumdar, including sales of 2,631 shares on March 4, 1,786 shares on March 5, 3,817 shares on March 6, and 36,766 shares on March 9, all in 2026. This activity provides insight into recent insider transactions and planned future sales for the company.
Bicara therapeutics CEO Mazumdar sells $282k in BCAX stock By Investing.com
Bicara Therapeutics CEO Claire Mazumdar sold 14,900 shares of BCAX common stock for approximately $282,365 between March 18 and March 20, 2026, while also exercising options to acquire an equal number of shares for $56,847. The stock performed well in the last six months, though InvestingPro indicates it's currently slightly overvalued. The company recently completed a $172.5 million public offering and received a "Market Outperform" rating from Citizens with a $31.00 price target.
Bicara Therapeutics (BCAX) president sells $245,713 in stock
Ryan Cohlhepp, President and COO of Bicara Therapeutics (NASDAQ:BCAX), sold 12,500 shares of common stock for approximately $245,713 on March 16, 2026. This sale occurred near the stock's 52-week high after a 76% surge in six months, though InvestingPro analysis suggests the stock is currently overvalued. Concurrently, Cohlhepp also exercised options to acquire 8,000 shares.
Bicara Therapeutics (BCAX) COO exercises options and sells shares
Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, exercised stock options for 8,000 shares and subsequently sold 12,500 shares of common stock. The sales were executed on March 16, 2026, at a weighted average price of $19.6571 per share, following a pre-arranged Rule 10b5-1 trading plan. After these transactions, Cohlhepp directly holds 200,641 shares of Bicara common stock.
